» Articles » PMID: 22665268

Fibulin-3 Promotes Glioma Growth and Resistance Through a Novel Paracrine Regulation of Notch Signaling

Overview
Journal Cancer Res
Specialty Oncology
Date 2012 Jun 6
PMID 22665268
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant gliomas are highly invasive and chemoresistant brain tumors with extremely poor prognosis. Targeting of the soluble factors that trigger invasion and resistance, therefore, could have a significant impact against the infiltrative glioma cells that are a major source of recurrence. Fibulin-3 is a matrix protein that is absent in normal brain but upregulated in gliomas and promotes tumor invasion by unknown mechanisms. Here, we show that fibulin-3 is a novel soluble activator of Notch signaling that antagonizes DLL3, an autocrine inhibitor or Notch, and promotes tumor cell survival and invasion in a Notch-dependent manner. Using a strategy for inducible knockdown, we found that controlled downregulation of fibulin-3 reduced Notch signaling and led to increased apoptosis, reduced self-renewal of glioblastoma-initiating cells, and impaired growth and dispersion of intracranial tumors. In addition, fibulin-3 expression correlated with expression levels of Notch-dependent genes and was a marker of Notch activation in patient-derived glioma samples. These findings underscore a major role for the tumor extracellular matrix in regulating glioma invasion and resistance to apoptosis via activation of the key Notch pathway. More importantly, this work describes a noncanonical, soluble activator of Notch in a cancer model and shows how Notch signaling can be reduced by targeting tumor-specific accessible molecules in the tumor microenvironment.

Citing Articles

Biosensor-Enhanced Organ-on-a-Chip Models for Investigating Glioblastoma Tumor Microenvironment Dynamics.

Thenuwara G, Javed B, Singh B, Tian F Sensors (Basel). 2024; 24(9).

PMID: 38732975 PMC: 11086276. DOI: 10.3390/s24092865.


Mechanism of Notch Signaling Pathway in Malignant Progression of Glioblastoma and Targeted Therapy.

Wang S, Gu S, Chen J, Yuan Z, Liang P, Cui H Biomolecules. 2024; 14(4).

PMID: 38672496 PMC: 11048644. DOI: 10.3390/biom14040480.


Engineering the glioblastoma microenvironment with bioactive nanoparticles for effective immunotherapy.

Blanchard R, Adjei I RSC Adv. 2023; 13(45):31411-31425.

PMID: 37901257 PMC: 10603567. DOI: 10.1039/d3ra01153d.


Fibulin2: a negative regulator of BMSC osteogenic differentiation in infected bone fracture healing.

Li S, Xing W, Wang S, Li Y, Jiang H, Zheng H Exp Mol Med. 2023; 55(2):443-456.

PMID: 36797542 PMC: 9981700. DOI: 10.1038/s12276-023-00942-0.


EFEMP1 binds to STEAP1 to promote osteosarcoma proliferation and invasion via the Wnt/β-catenin and TGF-β/Smad2/3 signal pathways.

Zhang D, Han S, Pan X, Li H, Zhao H, Gao X J Bone Oncol. 2022; 37:100458.

PMID: 36388640 PMC: 9643485. DOI: 10.1016/j.jbo.2022.100458.


References
1.
Berens M, Giese A . "...those left behind." Biology and oncology of invasive glioma cells. Neoplasia. 2000; 1(3):208-19. PMC: 1508082. DOI: 10.1038/sj.neo.7900034. View

2.
Kanamori M, Kawaguchi T, Nigro J, Feuerstein B, Berger M, Miele L . Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg. 2007; 106(3):417-27. DOI: 10.3171/jns.2007.106.3.417. View

3.
Nuovo G, Hagood J, Magro C, Chin N, Kapil R, Davis L . The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol. 2011; 25(3):416-33. PMC: 3270219. DOI: 10.1038/modpathol.2011.166. View

4.
Lindsell C, Shawber C, Boulter J, Weinmaster G . Jagged: a mammalian ligand that activates Notch1. Cell. 1995; 80(6):909-17. DOI: 10.1016/0092-8674(95)90294-5. View

5.
Hulleman E, Quarto M, Vernell R, Masserdotti G, Colli E, Kros J . A role for the transcription factor HEY1 in glioblastoma. J Cell Mol Med. 2008; 13(1):136-46. PMC: 3823042. DOI: 10.1111/j.1582-4934.2008.00307.x. View